Cargando...
Recombinant factor VIII Fc for the treatment of haemophilia A
Prophylaxis with factor VIII (FVIII) is the current therapeutic approach for people with haemophilia A. However, standard half‐life (SHL) FVIII products must be injected frequently, imposing a substantial burden on the individual and making it difficult to tailor therapy according to patient need an...
Gardado en:
| Publicado en: | Eur J Haematol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8252769/ https://ncbi.nlm.nih.gov/pubmed/33650192 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13610 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|